Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination with the PARP Inhibitor Olaparib in Patients with KRAS G12C Mutated Advanced Solid Tumors, with a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers
Latest Information Update: 25 Apr 2025
At a glance
Most Recent Events
- 22 Apr 2025 Planned primary completion date changed from 25 Aug 2030 to 25 Aug 2028.
- 30 Jul 2024 Planned primary completion date changed from 25 Aug 2028 to 25 Aug 2030.
- 30 Jan 2024 Status changed from not yet recruiting to recruiting.